Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
PSMA-targeted radioligand therapy
10 evidence topics · 7 sources
FDA-approved indication in androgen pathway modulation-resistant prostate cancer
Taxane-naive disease after one ARPI: trial population and crossover
Taxane-naive disease after one ARPI: efficacy versus a change in ARPI
| Outcome | Lutetium Lu 177 vipivotide tetraxetan | Change in ARPI | Hazard ratio (95% CI) |
|---|---|---|---|
| Radiographic progression-free survival, median months (95% CI) | “9.3 (7, NE)” | “5.6 (4, 6)” | “0.41 (0.29, 0.56)” |
| Overall survival, median months (95% CI) | “24.5 (19.5, 28.9)” | “23.1 (19.6, 25.5)” | “0.91 (0.72, 1.14)” |
Taxane-naive disease after one ARPI: updated radiographic progression-free survival and safety
“In an updated analysis at the third interim overall survival analysis, the HR for rPFS was 0·49 (95% CI, 0·39–0·61; median rPFS, 11·60 months [95% CI, 9·30–14·19] vs 5·59 [4·21–5·95]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of grade 3–5 adverse events was lower with 177 Lu-PSMA-617 vs ARPI change (81/227 [36%] vs 112/232 [48%]; grade 3–4, 80/227 [35%] vs 111/232 [48%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease after ARPI and taxane chemotherapy: overall survival versus best standard of care
| Outcome | Lutetium Lu 177 vipivotide tetraxetan plus best standard of care | Best standard of care | Hazard ratio (95% CI) |
|---|---|---|---|
| Overall survival, median months (95% CI) | “15.3 (14.2, 16.9)” | “11.3 (9.8, 13.5)” | “0.62 (0.52, 0.74)” |
Disease after ARPI and taxane chemotherapy: imaging-based progression-free survival and adverse events
“177 Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of adverse events of grade 3 or above was higher with 177 Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote